IL-2-based immunotherapies have shown great potential in cancer treatment, with several strategies currently in development to achieve immunostimulation without activating suppressive Tregs, including IL-2 muteins, PEGylated IL-2, IL-2/anti-IL-2 Ab complex, and IL-2-CD25 fusion proteins. This evidence concerns the gene IL2 and cancer.